United Therapeutics acquires Thymmune Therapeutics
Analysis based on 8 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026
The acquisition of Thymmune Therapeutics, Inc. by United Therapeutics is expected to positively impact United Therapeutics' stock price due to the expansion of its regenerative medicine pipeline and potential for new therapies. This event could also signal increased investor interest in the broader biotechnology sector, particularly in companies focused on cell therapies and organ regeneration.
United Therapeutics Corporation has acquired Thymmune Therapeutics, Inc., a privately held biotechnology company specializing in regenerative thymic cell therapies. The deal involves an upfront cash payment of $140 million, with potential earn-out payments of up to $160 million contingent on clinical and regulatory milestones by 2031. Thymmune Therapeutics, Inc.'s lead candidate, THY-100, is in preclinical development for congenital athymia and aims to restore T-cell function. This acquisition strengthens United Therapeutics' position in organ alternatives and immunomodulatory therapeutics, aligning with its mission to address rare diseases and expand the supply of transplantable organs. Martine Rothblatt and Wang Qiang both emphasized the strategic fit and potential impact on human health.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard